Swiss CDMO Dottikon Exclusive Synthesis (ES) is in the process of investing around CHF 700 million (€730 million) in new production and drying plants for APIs at its production site in Dottikon. Of this, CHF 400 million has already been spent, with half of the rest coming in the current business year to 31 March 2025.
Drug development services supplier CatSci has acquired its UK compatriot Reach Separations. No financial details were disclosed but the company said that this deal was supported by Keensight Capital, a private equity manager dedicated to pan-European growth buyout investments. The whole of the Reach Separations will transfer and the companies will be fully integrated.
The European Commission has informed India’s Alchem International and its Hong Kong subsidiary of its preliminary view “that they have breached EU antitrust rules by participating in a long-lasting cartel concerning an important pharmaceutical product”. If the EC ultimately concludes that there is sufficient evidence of an infringement, it can impose a fine of up to 10% of the company's worldwide turnover.
Swiss CDMO Siegfried has signed binding agreements with Curia Global for the acquisition of a drug substances site in Grafton, Wisconsin. The deal is expected to close by 1 July, subject to customary closing conditions. No financial details are being disclosed, other than that the acquisition is being financed from existing funds and will not change the company’s outlook for 2024 and mid-term financial targets.
Luxembourg-based OCSiAl has completed construction of a 3,000 tonnes/year facility for water-based single-wall carbon nanotube (SWCNT) dispersions in Serbia to support the manufacture of high-performance batteries. It is due to begin production in Q3.
Featuring cleanroom-operated production lines, this facility is an optimised version of the previous generation, with 15 times higher output. Much of the output is contracted with global electric vehicle producers and collaborations with the world’s largest lithium-ion battery cell manufacturers, the company said.
The European Commission has approved the first Important Project of Common European Interest (IPCEI). Under IPCEI Med4Cure, member states will provide up to €1 billion in public funding, which is expected to unlock €5.9 billion more in private funding.
Formosa Laboratories, a Taiwan-based API supplier and CDMO, has completed the acquisition of SynChem, a contract research laboratory located in suburban Chicago. SynChem will now operate as SynChem-Formosa, with Dr W. Paul Mar continuing as CEO. Terms were not disclosed.
